Eesti - eesti - Ravimiamet

norbrook laboratories limited - marbofloksatsiin - närimistablett - 5mg 98tk; 5mg 42tk; 5mg 70tk; 5mg 28tk; 5mg 56tk; 5mg 280tk; 5mg 14tk; 5mg 84tk

Eesti - eesti - Ravimiamet

norbrook laboratories limited - marbofloksatsiin - närimistablett - 20mg 84tk; 20mg 49tk; 20mg 14tk; 20mg 56tk; 20mg 42tk; 20mg 70tk; 20mg 28tk; 20mg 280tk; 20mg 98tk

Eesti - eesti - Ravimiamet

norbrook laboratories limited - karprofeen - tablett - 50mg 100tk; 50mg 20tk; 50mg 500tk

Eesti - eesti - Ravimiamet

norbrook laboratories limited - tülosiin - süstesuspensioon - 150mg 1ml 100ml 1tk

Eesti - eesti - Ravimiamet

norbrook laboratories limited - doramektiin - kriipsulahus - 5mg 1ml 5000ml 1tk; 5mg 1ml 2500ml 1tk; 5mg 1ml 1000ml 1tk; 5mg 1ml 10000ml 1tk; 5mg 1ml 250ml 1tk

Eesti - eesti - Ravimiamet

norbrook laboratories limited - fiproniil - nahasprei, lahus - 2,5mg 1ml 100ml 1tk; 2,5mg 1ml 250ml 1tk

Eesti - eesti - Ravimiamet

norbrook laboratories limited - kaltsiumglükonaat+boorhape+glükoos+magneesiumhüpofosfit - süstelahus - 166mg+34mg+220mg+50mg 1ml 400ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - abirateroonatsetaat - eesnäärmevähk - endokriinset ravi - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - abirateroonatsetaat - eesnäärmevähk - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Euroopa Liit - eesti - EMA (European Medicines Agency)

krka, d.d., novo mesto - abirateroonatsetaat - eesnäärmevähk - endokriinset ravi - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.